biologics

What more transparency at the FDA means for health executivesResearchers create a set of recommendations for transparency at the agency in five principal areas.
Therapies for hidradenitis suppurativaTNF inhibitors adalimumab and infliximab have evidence-based efficacy for the treatment of hidradentitis suppurativa (HS). Anti-interleukin inhibitors ustekinumab and anakinra also being evaluated in small studies for treatment of HS. Antibiotics, hormones, retinoids, steroids and laser therapies directly targeting the lesions round out an effective treatment plan for HS patients.
Business Group Makes Price Recommendations for Specialty Drugs
Business Group Makes Price Recommendations for Specialty DrugsThe high cost of specialty drugs demands a change in Washington, according to a report.
January Clinical Considerations for NPs, PAsThis month, we take a look at when to use biologics, advances in pediatric Atopic Dermatitis (AD), and how Trump’s presidency might impact dermatology.
Five things physicians don’t know about biosimilarsAwareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.
Psoriasis research: IL-17, comorbidities take center stageBased on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
Biologics, acetaminophen and the multimillion-dollar lawsuitAre doctors liable when patients combine acetaminophen with biologic medications used to treat psoriasis?
Clinical pearls for treating uveitisUveitis presents particular problems for ophthalmologists. Inflammation inside the eye can occur from so many causes that the diagnosis often requires painstaking, time-consuming investigation. As researchers have learned more about the disease, the possible etiologies and treatments have multiplied.
Real-world results determine value-based price for specialty drugsIn an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.